Guided Internet-Based Treatment for Harmful Alcohol Use; EBehandling Alkohol
eBA
2 other identifiers
interventional
250
1 country
5
Brief Summary
Guided internet-based treatment for individuals with harmful alcohol use, eBehandling Alkohol (eBA), will be implemented as an experimental treatment option in five hospitals autumn 2024. Concurrently, a research project related to the effects of eBA will be conducted. Results from a pilot project show that treatment with eBA can help reduce alcohol use and improve mental health among people with harmful alcohol consumption. Similar results have been found in other international studies. Many individuals with harmful alcohol consumption avoid seeking treatment, leading to negative consequences for the individual, their families, and society. The pilot project indicates that guided internet-based treatment is an effective treatment that is easily accessible and cost-effective. Access to eBA can help circumvent shame and stigma, increase access to treatment, reduce alcohol use, and improve physical and mental health. Individuals who wish to participate in eBA do not need a referral from a GP. After an initial screening, participants will be given access to eBA, which consists of 9 treatment modules to be completed over an 8-12-week period, upon giving their consent. Participants will be followed up 4 weeks, 6 months, and 2 years after the completion of treatment. Data will be collected during screening, throughout the treatment period, and post-treatment. Data will be collected in the form of questionnaires, interviews, and registry data. Simultaneously with the implementation of eBA as an experimental treatment, this project aims to investigate the characteristics of participants who apply for eBA, as well as examine the effects eBA may have in terms of reducing alcohol use, improving physical and mental health, and enhancing the quality of life among participants. The overarching goal of the study is to strengthen the understanding of the effects of internet-based treatment, thereby providing a sufficient basis to assess whether eBA should be implemented as a regular treatment option. The study will also be part of a larger collaborative project where we will conduct meta-analyses of results from eBA and two other studies that also include treatment programs aimed at individuals with varying degrees of alcohol problems: the "Predictor Study" and "Endre". The three treatment programs are aimed at individuals who are at different stages in their problem trajectory. The goal of this collaborative project is to contribute to the development of a more holistic and targeted treatment offer for individuals with varying degrees of problem development.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Nov 2024
Longer than P75 for not_applicable
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 20, 2024
CompletedFirst Submitted
Initial submission to the registry
November 27, 2024
CompletedFirst Posted
Study publicly available on registry
December 18, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2029
December 18, 2024
December 1, 2024
2.5 years
November 27, 2024
December 12, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (6)
Identifying characteristics of people seeking eBA
Describe demographics, age, sex, education, occupation, main source of income, marital status, children, duration of problem, previous treatment experience
Baseline measure
Changes in alcohol use
Measure changes using the Alcohol Use Disorder Scale (AUDIT ), reporting on a sum score scale from 0 to 40; higher score indicate worse outcome.
Measure changes from baseline to end of treatment, and 6 months and 2 years post-treatment
Changes in mental health status
Measure changes in SCL-10R (Symptom Check List) scores on a scale from 1 to 4, the higher score the wore outcome.
Measure changes from baseline to end of treatment, and 6 months and 2 years post-treatment
Changes in mental health status
Measure changes using GAD-7 (Generalized Anxiety Disorder), reporting on a scale from 0 to 3; higher score indicating worse outcome.
Measure changes from baseline to end of treatment, and 6 months and 2 years post-treatment
Changes in quality of life
Measure changes in 5Q-5D-5L (quality of life ), including av visual analoge scale (VAS). The 5Q-5D-5L scores on a scale from 1 to 5, were high score indicate worse outcome. The instrument includes a VAS from 0 to 100, where higher score indicate better outcome.
Measure changes from baseline to end of treatment, and 6 months and 2 years post-treatment
Changes in quality of life
Measure changes in WHO quality of life score (WHOQOL-1) on a scale from 1 to 5, where higher scores indicate better outcome.
Measure changes from baseline to end of treatment, and 6 months and 2 years post-treatment
Secondary Outcomes (3)
Compare participants characteristics in the eBA study, the Predictor Study and the Endre study
Baseline measure
Compare retention in treatment in eBA to standard group-treatment in the Predictor study and the Endre program
End of treatment program
Compare changes in alcohol use between participants in the eBA study, the Predictor study and the Endre study
Measure changes from baseline to end of treatment, and 6 months and 2 years post-treatment
Study Arms (1)
eBA intervention
EXPERIMENTALAdults with harmful alcohol use will be offered to complete a therapy-guided internet based intervention.
Interventions
eBA is a guided internet-based treatment for problematic alcohol use, based on cognitive behavioural therapy and motivational interview. The patients get access to self-help modules with information, questionnaires, and tools useful in a process of reducing alcohol use. Questionnaires measuring changes in alcohol use, illicit drug use, physical and mental health, and quality of life are frequently answered. These questionnaires are an integrated part of the treatment program and are used by the therapist to monitor and adjust the treatment according to each patient. The patients use the results from the questionnaires to assess whether the treatment is helpful reaching the treatment goal. The patients are guided by a therapist, and they communicate using a system for written messages in the treatment program and/ or guided by telephone.
Eligibility Criteria
You may qualify if:
- Harmful alcohol use
- Willing to make an effort to reduce alcohol consumption
- Able to use guided internet-based treatment
- Access to a computer, tablet, or smartphone
- Access to BankID or equivalent secure log-in
You may not qualify if:
- \* Acute and/or severe mental disorders, such as psychotic issues or ongoing suicidal issues.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sykehuset i Vestfold HFlead
- Sykehuset Innlandet HFcollaborator
- University Hospital, Akershuscollaborator
- Hospital of Southern Norway Trustcollaborator
- Trondheim University Hospitalcollaborator
Study Sites (5)
Sørlandet Hospital Trust (Hospital of Kristiansand)
Kristiansand, Agder, 4604, Norway
Akershus University Hospital
Loerenskog, Akershus, 1478, Norway
Innlandet Hospital Trust
Lillehammer, Innlandet, 2629, Norway
St. Olavs Hospital
Trondheim, Trøndelag, 7006, Norway
Vestfold Hospital Trust
Tønsberg, Vestfold, 3103, Norway
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Kristin K Solli, PhD
Sykehuset i Vestfold HF
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Project leader
Study Record Dates
First Submitted
November 27, 2024
First Posted
December 18, 2024
Study Start
November 20, 2024
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
December 1, 2029
Last Updated
December 18, 2024
Record last verified: 2024-12
Data Sharing
- IPD Sharing
- Will not share
With the aim of doing a meta analysis, we will share anonymized aggregated data at the group level with the research leaders of the Predictor study and the Endre study. In consideration of the participating patients' rights, we will not share individual participant data.